|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC25A40 |
Gene summary for SLC25A40 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC25A40 | Gene ID | 55972 |
| Gene name | solute carrier family 25 member 40 | |
| Gene Alias | MCFP | |
| Cytomap | 7q21.12 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8TBP6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55972 | SLC25A40 | LZE4T | Human | Esophagus | ESCC | 1.95e-07 | 1.36e-01 | 0.0811 |
| 55972 | SLC25A40 | LZE7T | Human | Esophagus | ESCC | 2.26e-02 | 2.20e-01 | 0.0667 |
| 55972 | SLC25A40 | LZE20T | Human | Esophagus | ESCC | 1.32e-03 | 1.18e-01 | 0.0662 |
| 55972 | SLC25A40 | LZE24T | Human | Esophagus | ESCC | 1.14e-13 | 2.71e-01 | 0.0596 |
| 55972 | SLC25A40 | P1T-E | Human | Esophagus | ESCC | 1.05e-02 | 9.88e-02 | 0.0875 |
| 55972 | SLC25A40 | P2T-E | Human | Esophagus | ESCC | 6.73e-18 | 3.41e-01 | 0.1177 |
| 55972 | SLC25A40 | P4T-E | Human | Esophagus | ESCC | 1.36e-14 | 1.69e-01 | 0.1323 |
| 55972 | SLC25A40 | P5T-E | Human | Esophagus | ESCC | 4.82e-08 | 2.00e-01 | 0.1327 |
| 55972 | SLC25A40 | P8T-E | Human | Esophagus | ESCC | 6.27e-06 | 1.24e-01 | 0.0889 |
| 55972 | SLC25A40 | P9T-E | Human | Esophagus | ESCC | 3.08e-08 | 1.29e-01 | 0.1131 |
| 55972 | SLC25A40 | P10T-E | Human | Esophagus | ESCC | 6.42e-16 | 2.59e-01 | 0.116 |
| 55972 | SLC25A40 | P11T-E | Human | Esophagus | ESCC | 6.39e-07 | 2.05e-01 | 0.1426 |
| 55972 | SLC25A40 | P12T-E | Human | Esophagus | ESCC | 2.65e-09 | 1.64e-01 | 0.1122 |
| 55972 | SLC25A40 | P15T-E | Human | Esophagus | ESCC | 3.43e-13 | 3.15e-01 | 0.1149 |
| 55972 | SLC25A40 | P16T-E | Human | Esophagus | ESCC | 4.83e-42 | 8.78e-01 | 0.1153 |
| 55972 | SLC25A40 | P19T-E | Human | Esophagus | ESCC | 4.50e-02 | 2.03e-01 | 0.1662 |
| 55972 | SLC25A40 | P20T-E | Human | Esophagus | ESCC | 3.43e-32 | 5.52e-01 | 0.1124 |
| 55972 | SLC25A40 | P21T-E | Human | Esophagus | ESCC | 5.69e-14 | 3.22e-01 | 0.1617 |
| 55972 | SLC25A40 | P22T-E | Human | Esophagus | ESCC | 6.18e-13 | 1.43e-01 | 0.1236 |
| 55972 | SLC25A40 | P23T-E | Human | Esophagus | ESCC | 3.52e-10 | 2.16e-01 | 0.108 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC25A40 | SNV | Missense_Mutation | c.145N>A | p.Pro49Thr | p.P49T | Q8TBP6 | protein_coding | deleterious(0.04) | benign(0.038) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| SLC25A40 | SNV | Missense_Mutation | rs778537970 | c.287N>A | p.Arg96Gln | p.R96Q | Q8TBP6 | protein_coding | tolerated(0.16) | possibly_damaging(0.49) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SLC25A40 | SNV | Missense_Mutation | rs778537970 | c.287N>A | p.Arg96Gln | p.R96Q | Q8TBP6 | protein_coding | tolerated(0.16) | possibly_damaging(0.49) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| SLC25A40 | SNV | Missense_Mutation | c.259N>C | p.Thr87Pro | p.T87P | Q8TBP6 | protein_coding | deleterious(0) | possibly_damaging(0.696) | TCGA-AD-A5EK-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SLC25A40 | SNV | Missense_Mutation | c.410N>C | p.Gly137Ala | p.G137A | Q8TBP6 | protein_coding | tolerated(0.21) | benign(0.026) | TCGA-AF-A56L-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
| SLC25A40 | SNV | Missense_Mutation | c.542N>A | p.Arg181Gln | p.R181Q | Q8TBP6 | protein_coding | tolerated(0.64) | benign(0.009) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
| SLC25A40 | insertion | Nonsense_Mutation | novel | c.464_465insCATGTAAAATTT | p.Ala155_Val156insMetTerAsnLeu | p.A155_V156insM*NL | Q8TBP6 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SLC25A40 | SNV | Missense_Mutation | c.542N>A | p.Arg181Gln | p.R181Q | Q8TBP6 | protein_coding | tolerated(0.64) | benign(0.009) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| SLC25A40 | SNV | Missense_Mutation | novel | c.746N>T | p.Ala249Val | p.A249V | Q8TBP6 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC25A40 | SNV | Missense_Mutation | c.542N>A | p.Arg181Gln | p.R181Q | Q8TBP6 | protein_coding | tolerated(0.64) | benign(0.009) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |